Alexipharmic Drugs Market
According to Intent Market Research, the Alexipharmic Drugs Market is expected to grow from USD 1.5 billion in 2023 at a CAGR of 6.9% to touch USD 2.4 billion by 2030. The Alexipharmic Drugs Market is dominated by key players such as AbbVie Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Eisai Co., Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc. and Takeda Pharmaceutical Company Limited.